Abstract:1169 Objectives The bradykinin B1 receptor (B1R), a G-protein coupled receptor, is overexpressed in several pathophysiological conditions including inflammation and cancer. B1R mediates nociception in the context of inflammation, and it is believed to contribute to tumourigenesis by promoting cell proliferation, invasion and angiogenesis. Previously, our lab reported the evaluation of several promising B1R-targeting peptides for cancer imaging. These peptides have high affinity to B1R and generate high-contrasted images of B1R-expressing tumour xenografts in mice. A significant number of potent B1R small molecule antagonists have been developed by pharmaceutical companies for the treatment of chronic pain, and could potentially be exploited for the design of B1R-targeting imaging agents. In this study, we investigated the use of an 18F-labeled small molecule (4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-[18F]fluoroethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide, 18F-Z02035) as an alternative to peptide-based B1R-imaging. Methods The non-radioactive Z02035 standard and its des-fluoroethyl precursor (4-methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-H-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide, Z02153) were synthesized via multi-step synthesis approach. The binding affinity of Z02035 for B1R was determined by in vitro competition binding assay using B1R-expressing cell membrane. 18F-Z02035 was prepared in two steps: (1) synthesis of 2-[18F]fluoroethyl tosylate by aliphatic nucleophilic substitution using 18F-fluoride and 1,2-bis(tosyloxy)ethane; and (2) coupling of 2-[18F]fluoroethyl tosylate with the precursor Z02153. PET imaging and biodistribution studies were performed at 1 h post-injection in mice bearing both B1R-positive HEK293T::hB1R and B1R-negative wild-type HEK293T tumours. Results The overall synthesis yield for the non-radioactive standard Z02035 was 1% (seven steps), and the yield for the precursor Z02153 was 47% (seven steps). Competition assays showed that Z02035 is a potent B1R binder with a Ki value of 0.93 ± 0.44 nM. By reacting Z02153 with 2-[18F]fluoroethyl tosylate, 18F-Z02035 was obtained in 6 ± 1% non-decay corrected yield with > 99% radiochemical purity and 0.9 ± 0.8 Ci/µmol specific activity. From PET images, 18F-Z02035 enabled visualization of the B1R-positive HEK293T::hB1R tumours with better contrast than the B1R-negative HEK293T tumours. In terms of clearance, 18F-Z02035 was excreted primarily through the hepatobiliary pathway. The average uptake in HEK293T::hB1R tumours (3.77 ± 0.79 %ID/g) was higher than in HEK293T tumours (2.11 ± 0.37 %ID/g). The tumour-to-muscle ratio for HEK293T::hB1R was 3.38 ±1.05. 18F-Z02035 exhibited slight defluorination in vivo as bone uptake was 4.63 ± 0.65 %ID/g. Conclusions We took a novel approach for targeting B1R expression by synthesizing an 18F-labeled small molecule. Although absolute uptake and overall contrast are lower than reported B1R tracers derived from peptide sequences, 18F-Z02035 was able to differentiate between B1R expressing and non-expressing tumour xenografts. Optimization to enhance tumour uptake/contrast and reduce in vivo defluorination is currently underway.

Radiosynthesis and <i>in vivo</i> evaluation of a new positron emission tomography radiotracer targeting bromodomain and extra-terminal domain (BET) family proteins

Development of a Novel Positron Emission Tomography (PET) Radiotracer Targeting Bromodomain and Extra-Terminal Domain (BET) Family Proteins.

The Development and Evaluation of a Novel Highly Selective PET Radiotracer for Targeting BET BD1

Positron emission tomography probes targeting bromodomain and extra-terminal (BET) domains to enable in vivo neuroepigenetic imaging.

Development of a PET Probe Targeting Bromodomain and Extra-Terminal Proteins for In Vitro and In Vivo Visualization

Synthesis and Characterization of a Positron Emission Tomography Imaging Probe Selectively Targeting the Second Bromodomain of Bromodomain Protein BRD4

Design, Synthesis, and Evaluation of Thienodiazepine Derivatives as Positron Emission Tomography Imaging Probes for Bromodomain and Extra-Terminal Domain Family Proteins

Development and Evaluation of [ 11 C]I-58: A Novel PET Radiotracer Targeting BRD4 BD2 for Advanced Epigenetic Imaging

Radiosynthesis and evaluation of acetamidobenzoxazolone based radioligand [C-11]N '-MPB for visualization of 18 kDa TSPO in brain

Preliminary PET imaging of [11C]evobrutinib in mouse models of colorectal cancer, SARS-CoV-2, and lung damage: Radiosynthesis via base-aided palladium-NiXantphos-mediated 11C-carbonylation

Radiolabelled Quinoline Derivaties for the PET Imaging of Peripheral Benzodiazepine Receptor

Labeling of Bruton's Tyrosine Kinase (BTK) Inhibitor [11C]BIO-2008846 in Three Different Positions and Measurement in NHP Using PET

Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression

Establishment of environment-sensitive probes targeting BRD3/BRD4 for imaging and therapy of tumor

Synthesis and Evaluation of an 18F-Labeled Bradykinin B1 Receptor-Targeting Small Molecule for PET Imaging

Radiolabeled B9958 Derivatives for Imaging Bradykinin B1 Receptor Expression with Positron Emission Tomography: Effect of the Radiolabel-Chelator Complex on Biodistribution and Tumor Uptake

Synthesis And Initial In Vivo Studies With [C-11]Sb-216763: The First Radio Labeled Brain Penetrative Inhibitor Of Gsk-3

Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development

Novel 18F-Labeled Isonicotinamide-Based Radioligands for Positron Emission Tomography Imaging of Glycogen Synthase Kinase-3β

Preclinical Evaluation Of Radiolabeled Negative Allosteric Modulators For Pet Imaging Of Metabotropic Glutamate Receptor 2

Discovery of Novel Small Molecule Induced Selective Degradation of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD4 and BRD2 with Cellular Potencies.